Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a United States-based late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases. The company is developing proprietary therapeutic drug products, with QRX003 as its lead program and additional work on QRX009 and topical rapamycin formulations.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical development of QRX003 for Netherton Syndrome and related rare skin diseases.
Development work on QRX009 and other rare-disease candidates.
Research into topical rapamycin-based formulations for orphan indications.
Activities supporting approvals, orphan designations, and launch readiness.
Asiakkaat
Quoin does not yet sell commercial products, so its near-term counterparties are primarily regulators, clinical investigators, trial participants, and development partners rather than end-market buyers. If approved, the company expects its therapies to be used by patients with rare genetic skin diseases, with commercialization supported through its own sales infrastructure in some markets and distribution partners in others. The value proposition is concentrated in diseases with limited or no approved treatments, where clinical benefit and regulatory designation can shape adoption.
Patients with Netherton Syndrome and related genetic skin disorders who would use QRX003 or similar therapies if approved.
Hospitals, investigators, and study coordinators that enroll and monitor patients in late-stage trials.
FDA, European, Japanese, and Saudi regulators that determine designations, trial requirements, and approval pathways.
Regional distribution and licensing partners that may help launch products outside Quoin's direct-sales markets.
Strategia
Quoin's strategy is centered on advancing QRX003 through late-stage clinical testing, securing regulatory designations, and preparing for commercialization in rare-disease markets. It is also expanding the pipeline through QRX009, topical rapamycin research, and external business development, while maintaining flexibility to partner, license, or pursue other transactions.
Regulatory approval is the main value-creation event for the lead asset and the basis for future revenue.
Rare-disease launches require specialized medical education, distribution, and market-access capabilities.
A second and third program can reduce single-asset dependency and extend long-term growth options.
Partnerships can speed geographic expansion and conserve internal resources in a capital-intensive model.
Maantiede
Quoin is headquartered in the United States and is building a multi-region regulatory and commercialization path for QRX003. Its planned launch footprint includes the U.S., Europe, and Japan directly, with partner-led distribution in Canada, Australia/New Zealand, the Middle East, China, Hong Kong, Taiwan, Latin America, Central and Eastern Europe, Turkey, and Singapore. Geography matters because rare-disease approvals, reimbursement, and partner structures differ materially across these markets.
Riskit
Quoin is exposed to the core risks of late-stage drug development: trial failure, delays, additional regulatory requirements, and uncertainty around approval pathways. As a pre-revenue biotechnology company, it also depends on external financing and may face dilution, restricted access to capital, and commercialization execution risk if any product is approved. Its single-lead-asset profile adds concentration risk until the pipeline broadens.
- Financing and dilution riskVaikutus: KriittinenTodennäköisyys: Korkea
The business is pre-revenue and depends on external capital to fund R&D and commercialization.
Kohdistuu - Clinical development failure or delayVaikutus: KriittinenTodennäköisyys: Kohtalainen
QRX003 and other candidates are still in late-stage testing and may not achieve the required efficacy, safety, or timelines.
Kohdistuu: Lead asset QRX003
- Regulatory uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
FDA and foreign agencies could require additional trials, different designs, or more evidence before approval.
Kohdistuu - Nasdaq listing riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Failure to meet continued listing requirements could threaten market access and investor confidence.
Kohdistuu: Nasdaq Capital Market
- Commercialization execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Even with approval, Quoin must build sales, market access, and distribution capabilities for rare-disease launches.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical program costs, payroll, and outsourced trial spending move with study timing and drive quarter-to-quarter volatility.
Vaikutus: Affects operating loss and comparability across periods
Equity awards create non-cash expense that can be meaningful for a development-stage biotech.
Vaikutus: Increases reported R&D and G&A expense
Licensed or acquired intellectual property is amortized over its useful life and included in R&D.
Vaikutus: Affects R&D expense and carrying value of IP
Cash runway depends on future financing and clinical spend, making disclosure quality important.
Vaikutus: Influences capital markets perception and solvency analysis
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Palvella Therapeutics, Inc
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
Eton Pharmaceuticals, Inc.
ETON · Pharmaceutical Preparations
ProQR Therapeutics N.V.
PRQR · Pharmaceutical Preparations
Quantum Biopharma Ltd.
QNTM · Pharmaceutical Preparations
Capricor Therapeutics, Inc
CAPR · Pharmaceutical Preparations
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Päivitetty: 28.9.2026